A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

S Halford; D Yip; C Karapetis; A Strickland; A. Steger; H T Khawaja; P Harper

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

S Halford, D Yip, C Karapetis, A Strickland, A. Steger, H T Khawaja, P Harper

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Original language	English
Pages (from-to)	1399-1402
Number of pages	4
Journal	Annals of Oncology
Volume	12
Issue number	10
Publication status	Published - 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{690c02a97f5e47c88f88a990db09f198,

title = "A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma",

author = "S Halford and D Yip and C Karapetis and A Strickland and A. Steger and Khawaja, {H T} and P Harper",

year = "2001",

language = "English",

volume = "12",

pages = "1399--1402",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "10",

}

TY - JOUR

T1 - A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

AU - Halford, S

AU - Yip, D

AU - Karapetis, C

AU - Strickland, A

AU - Steger, A.

AU - Khawaja, H T

AU - Harper, P

PY - 2001

Y1 - 2001

M3 - Article

SN - 0923-7534

VL - 12

SP - 1399

EP - 1402

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -